4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) – Equities researchers at SVB Leerink lowered their FY2023 EPS estimates for 4D Molecular Therapeutics in a report issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar now anticipates that the company will post earnings per share of ($2.96) for the year, down from their prior estimate of ($2.95). SVB Leerink has a “Market Perform” rating and a $11.00 price target on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($3.25) per share. SVB Leerink also issued estimates for 4D Molecular Therapeutics’ FY2024 earnings at ($2.46) EPS.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.06. The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $1.70 million. 4D Molecular Therapeutics had a negative return on equity of 36.94% and a negative net margin of 5,331.88%.
4D Molecular Therapeutics Trading Up 5.1 %
NASDAQ FDMT opened at $20.86 on Wednesday. The business’s 50-day moving average price is $22.04 and its 200 day moving average price is $13.56. 4D Molecular Therapeutics has a twelve month low of $5.32 and a twelve month high of $26.49. The company has a market capitalization of $675.66 million, a PE ratio of -6.26 and a beta of 2.77.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Amalgamated Bank acquired a new position in 4D Molecular Therapeutics in the 1st quarter worth $53,000. Ensign Peak Advisors Inc increased its position in shares of 4D Molecular Therapeutics by 167.9% during the third quarter. Ensign Peak Advisors Inc now owns 7,180 shares of the company’s stock worth $58,000 after acquiring an additional 4,500 shares during the last quarter. Barclays PLC increased its position in shares of 4D Molecular Therapeutics by 18.3% during the third quarter. Barclays PLC now owns 11,376 shares of the company’s stock worth $91,000 after acquiring an additional 1,760 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of 4D Molecular Therapeutics by 83.5% in the second quarter. SG Americas Securities LLC now owns 15,309 shares of the company’s stock worth $107,000 after acquiring an additional 6,967 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in 4D Molecular Therapeutics by 38.8% in the second quarter. Price T Rowe Associates Inc. MD now owns 15,790 shares of the company’s stock valued at $110,000 after purchasing an additional 4,415 shares during the last quarter. 79.94% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other 4D Molecular Therapeutics news, CEO David Kirn sold 10,899 shares of the business’s stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $20.03, for a total transaction of $218,306.97. Following the completion of the sale, the chief executive officer now directly owns 1,902,224 shares in the company, valued at $38,101,546.72. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other 4D Molecular Therapeutics news, CEO David Kirn sold 10,899 shares of the business’s stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $20.03, for a total transaction of $218,306.97. Following the transaction, the chief executive officer now owns 1,902,224 shares in the company, valued at $38,101,546.72. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Scott Bizily sold 6,000 shares of the company’s stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $22.79, for a total value of $136,740.00. Following the completion of the sale, the insider now directly owns 2,482 shares of the company’s stock, valued at approximately $56,564.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,832 shares of company stock valued at $1,131,936. 11.22% of the stock is currently owned by corporate insiders.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
- Get a free copy of the StockNews.com research report on 4D Molecular Therapeutics (FDMT)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.